Equities analysts expect that Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) will announce earnings of ($0.28) per share for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Merrimack Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.45) and the highest is $1.69. Merrimack Pharmaceuticals posted earnings of ($2.50) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 88.8%. The firm is scheduled to announce its next earnings results on Wednesday, March 7th.
On average, analysts expect that Merrimack Pharmaceuticals will report full-year earnings of $36.83 per share for the current financial year, with EPS estimates ranging from $35.27 to $38.38. For the next fiscal year, analysts forecast that the business will report earnings of ($5.44) per share, with EPS estimates ranging from ($7.62) to ($4.26). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Merrimack Pharmaceuticals.
A number of equities research analysts recently commented on the stock. ValuEngine upgraded shares of Merrimack Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th. Robert W. Baird restated a “hold” rating and issued a $15.00 price objective on shares of Merrimack Pharmaceuticals in a research report on Friday, October 13th. Finally, Zacks Investment Research downgraded shares of Merrimack Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th.
Merrimack Pharmaceuticals (MACK) traded down $0.13 during midday trading on Friday, hitting $10.22. The company had a trading volume of 238,500 shares, compared to its average volume of 258,532. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.35 and a current ratio of 3.35. Merrimack Pharmaceuticals has a 52-week low of $10.04 and a 52-week high of $54.80.
About Merrimack Pharmaceuticals
Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.